EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase III)

Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial

Richard M Bergenstal iD, Björg Ásbjörnsdóttir, Tanvir Johanning Bari, Satish Hulkund, Yvonne Winhofer, Carol Wysham iD

Diabetes Technology & Therapeutics · 2025

DOI: 10.1089/dia.2025.0050 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes Technology & Therapeutics, 2025. Verfasst von Richard M Bergenstal und 5 weiteren Autor:innen. Beteiligte Einrichtung: International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Blood Glucose Self-Monitoring, Blood Glucose. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

ONWARDS 9 explored, for the first time, the effect of continuous glucose monitoring (CGM)-based titration of once-weekly insulin icodec (icodec) on glycemic control and safety outcomes in individuals with type 2 diabetes (T2D).

Methods

In this 26-week, multicenter, single-arm, treat-to-target, phase 3b trial, insulin-naive adults with T2D (glycated hemoglobin [HbA1c] 7.0%-11.0%) initiated icodec at a starting dose of 70 U/week. Participants were provided with an intermittently scanned CGM device, and icodec doses were titrated weekly based on pre-breakfast CGM values (target: 80-130 mg/dL). The primary endpoint was change in HbA1c from week 0 to week 26. Exploratory endpoints included the percentage of time in range (TIR; 70-180 mg/dL), time above range (TAR; >180 mg/dL), and time below range (TBR; 180 mg/dL, and TBR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsBlood Glucose Self-MonitoringBlood GlucoseInsulinHumansMaleFemaleMiddle AgedGlycated HemoglobinAgedAdultGlycemic ControlHypoglycemiaDrug Administration ScheduleTreatment OutcomeContinuous Glucose Monitoring

Stichwörter der Autor:innen

continuous glucose monitoringinsulin titrationonce-weekly insulintype 2 diabetes

Substanzen

Hypoglycemic AgentsGlycated HemoglobinBlood GlucoseInsulinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • International Diabetes Center, HealthPartners Institute, Minneapolis, Minnesota, USA.
  • Novo Nordisk A/S, Søborg, Denmark.
  • Division of Endocrinology and Metabolism, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Division of Endocrinology and Diabetes, Multicare/Rockwood Clinic, Spokane, Washington, USA.

ORCID-Profile: Richard M Bergenstal, Carol Wysham

Zitieren

APA

Bergenstal, R. M., Ásbjörnsdóttir, B., Johanning Bari, T., Hulkund, S., Winhofer, Y., & Wysham, C. (2025). Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial. Diabetes Technology & Therapeutics. https://doi.org/10.1089/dia.2025.0050

Vancouver

Bergenstal RM, Ásbjörnsdóttir B, Johanning Bari T, Hulkund S, Winhofer Y, Wysham C. Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial. Diabetes Technology & Therapeutics. 2025. doi:10.1089/dia.2025.0050

BibTeX
@article{Bergenstal2025,
  author = {Bergenstal, Richard M and Ásbjörnsdóttir, Björg and Johanning Bari, Tanvir and Hulkund, Satish and Winhofer, Yvonne and Wysham, Carol},
  title = {Continuous Glucose Monitoring-Based Titration of Once-Weekly Insulin Icodec in Insulin-Naive Individuals with Type 2 Diabetes (ONWARDS 9): A Phase 3b, Multicenter, Single-Arm, Treat-to-Target Clinical Trial},
  journal = {Diabetes Technology & Therapeutics},
  year = {2025},
  doi = {10.1089/dia.2025.0050}
}
Kostenlos starten →